The main differences between bipolar 1 and bipolar 2 are the severity of manic episodes, and whether or not someone ...
Bipolar disorder affects about 4% of the US population and causes symptoms like depression, fatigue, impulsivity, and periods of high energy.
The Walsh Research Institute (WRI) announces a major scientific breakthrough in understanding bipolar disorder, revealed in The Essence of Bipolar Disorder by William J. Walsh, Ph.D. (Skyhorse ...
This is a developing news story. Please check back soon for updates. The FDA approved extended-release Uzedy for the ...
After single-blind placebo run-in periods of ≤7 days, patients were randomly assigned to 3 weeks of sublingual asenapine (10 mg twice daily [BID] on day 1, flexible-dose 5 or 10 mg BID thereafter), ...
The Independent on MSN
Gucci Mane offers health update after revealing bipolar disorder and schizophrenia diagnoses
Gucci Mane offers health update after revealing bipolar disorder and schizophrenia diagnoses - The rapper revealed his ...
Hosted on MSN
Bipolar Research & Insights: Inflammation, Hep C, High Blood Sugar, and More | August 2025
Studies on autoimmune diseases, hepatitis C, and diabetes show just how connected bipolar disorder is to whole-body health — and point to treatments and habits that could help. Living with bipolar ...
GlobalData on MSN
FDA approves Teva and Medincell’s bipolar I disorder treatment
Teva Pharmaceuticals and Medincell have gained approval from the US Food and Drug Administration (FDA) for Uzedy (risperidone ...
Dr. Calabrese answers the question: 'When Can I Stop Taking Bipolar Meds?' — -- Question: How long do I have to take medication for bipolar disorder, and can I stop if I no longer have symptoms?
In 2021, I built a small but amazing team and founded a boutique mental health marketing company, Priceless Copy. One year into running my business, life took an unexpected turn. I discovered a ...
Paris: The FDA has approved UZEDY, the first subcutaneous long-acting risperidone formulation utilizing SteadyTeq™ technology ...
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback